Results 141 to 150 of about 103,365 (348)

Semaglutide versus Tirzepatide - comparison of both drugs in treatment of diabetes type 2 and weight reduction

Quality in Sport
In recent years, the popularity of drugs which were firstly introduced as treatment for diabetes type 2 has surged, because of their’s significant effect of managing the body weight especially for patients that suffer for diabetes type 2.
Arkadiusz Staroń, Patrycja Karkos, Katarzyna Kuśmierczyk, Bartłomiej Gastoł, Karolina Mikołap, Marta Kras, Marta Jurga   +6 more
doaj   +1 more source

Expanding the genotypic spectrum of PCSK1 deficiency: A novel mutation in severe neonatal diarrhea

JPGN Reports, EarlyView.
Abstract Among congenital diarrhea and enteropathies (CODEs), proprotein convertase subtilisin/kexin type 1 (PCSK1) deficiency is a rare monogenic disorder, associated with severe neonatal diarrhea and polyendocrinopathies. We report an 18‐day‐old male neonate, born to consanguineous parents, presenting with persistent watery diarrhea, metabolic ...
Eleonora Saraceno, Angelo Corso Faini, Silvia Deaglio, Marianna Pellegrini, Raffaele Buganza, Francesca Giuliani, Pier Luigi Calvo, Michele Pinon   +7 more
wiley   +1 more source

Preliminary evidence of improved liver biomarkers in adolescents with obesity and suspected metabolic dysfunction‐associated steatotic liver disease treated with semaglutide: A case series

JPGN Reports, EarlyView.
Abstract Metabolic dysfunction‐associated steatotic liver disease (MASLD) affects 30%–40% of youth with obesity and lacks approved pharmacologic therapies. In this single‐center retrospective case series at a tertiary care safety‐net children's hospital, we evaluated five adolescents (mean age: 17.0 years; 100% Hispanic; 60% male; mean body mass index:
Rachel Schenker, Katya Fomenko, Fotini T. Mitsinikos, Alaina P. Vidmar   +3 more
wiley   +1 more source

A narrative review of glucagon-like peptide-1 receptor agonists prior to deep sedation or general anesthesia

Journal of Anesthesia, Analgesia and Critical Care
Glucagon-like peptide-1 receptor agonists are a class of drugs that mimic a natural incretin hormone released by the intestine after meals, and they are well-suited for treating type 2 diabetes.
Luigi Vetrugno, Cristian Deana, Andrea Da Porto, Enrico Boero, Valentina Bellini, Daniele Guerino Biasucci, Elena Giovanna Bignami   +6 more
doaj   +1 more source

A glucagon-like peptide-1 receptor agonist reduces intracranial pressure in a rat model of hydrocephalus

, 2017
Hannah Botfield, Maria Uldall, Connar Stanley James Westgate, James Mitchell, Snorre Malm Hagen, Ana María Gonzalez, David J. Hodson, Rigmor Jensen, Alexandra J. Sinclair   +8 more
openalex   +2 more sources

Glucagon-Like Peptide-1 Receptor Controls Exocytosis in Chromaffin Cells by Increasing Full Fusion Events

, 2020
Ayoze González‐Santana, Judith Estévez‐Herrera, Elizabeth P. Seward, Ricardo Borges, José David Machado   +4 more
openalex   +1 more source

PERCC1‐associated enteropathy: Diagnostic challenges and enteral autonomy achieved with teduglutide

JPGN Reports, EarlyView.
Abstract Congenital diarrheas and enteropathies (CODE) are rare inherited disorders characterized by early‐onset intractable diarrhea. Though progress has been made in elucidating the genetic basis of CODE, much remains to be discovered. Another challenge is the lack of curative therapies—treatment is primarily supportive including enteral and ...
Angela Tran, Vivien Nguyen, Phuong Huynh
wiley   +1 more source

Obesity Treatments to Improve Type 1 Diabetes (OTID): a randomized controlled trial of the combination of glucagon-like peptide 1 analogues and sodium-glucose cotransporter 2 inhibitors—protocol for Obesity Treatments to Improve Type 1 Diabetes (the OTID trial)

Trials
Background The guidelines of the American Diabetes Association and European Association for the Study of Diabetes suggest that patients with obesity type 2 diabetics and chronic kidney disease need either glucagon-like peptide 1 receptor analogues or ...
Ebaa Al-Ozairi, Kavita Narula, Alexander D. Miras, Etab Taghadom, Abeer El Samad, Jumana Al Kandari, Anas Alyosef, Anant Mashankar, Werd Al-Najim, Carel W. le Roux   +9 more
doaj   +1 more source

Recent clinical and pharmacological advancements of incretin-based therapy and the effects of incretin on physiology

Journal of Diabetology
A novel therapeutic target for diabetes mellitus is incretin-based therapies, glucagon-like peptide-1, and glucose-dependent insulinotropic polypeptides are released from the gastrointestinal (GI) tract and act on beta cells of pancreatic islets by ...
Bhaskar Pal, Moitreyee Chattopadhyay
doaj   +1 more source

Associations Between GLP‐1 Receptor Agonists and Alopecia: A Multi‐Centre Retrospective Analysis and Public Interest Trends

JEADV Clinical Practice, EarlyView.
ABSTRACT Background There is a growing body of literature suggesting that GLP‐1 receptor agonists (GLP‐1RAs) may be associated with hair loss; however, primary literature is sparse. Additionally, it is not well‐established which types of hair loss may be associated with GLP‐1RA use. Objectives This study aims to assess associations between GLP‐1RAs and
Lauren M. Ching, Christopher A. Guirguis, Joe K. Tung   +2 more
wiley   +1 more source